Patients taking tiotropium via the Respimat mist inhaler are at an increased risk of dying, a meta-analysis of placebo-controlled trials suggests. In the study, published online in the BMJ (14 June 2011), researchers analysed mortality data from five trials comparing tiotropium via Respimat with placebo for patients with chronic obstructive pulmonary disease. Patients had been treated for more than a month. Inhaling tiotropium via Respimat was shown to be associated with an increased risk of mortality (relative risk 1.52, P=0.02), a finding that was significant for both the 5ug and 10μg doses.
展开▼
